All In Biotech

Drug Trial Radar · NCT04569227

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 30, 2026

Primary completion

Dec 30, 2027

Study completion Jan 1, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19

Conditions

  • Covid19 Pneumonia

Interventions

  • EC-18Drug

    2000 mg PO daily

  • PlaceboDrug

    PO daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients alive and free of respiratory failure through at Day 28Time frame: 28 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Lincoln Medical Center

    The Bronx, New York

  • Kent County Memorial Hospital

    Warwick, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.